November 05, 2025

Get In Touch

Oral Methotrexate Safe And Effective Treatment Option For Severe Alopecia Areata: Study

Canada: Oral methotrexate (MTX) may be a feasible treatment option for patients with severe alopecia areata (AA) who fail other standard therapies, finds a recent study in the Journal of Cutaneous Medicine and Surgery.
None of the suggested therapeutic options for alopecia areata have been consistently effective thus, making the management of severe or refractory cases challenging. Several studies have shown the use of methotrexate (MTX) in alopecia areata (AA); however, the pure effect of methotrexate (MTX) monotherapy remains elusive. Considering the same, Misaki Kinoshita-Ise, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues aimed to evaluate efficacy and safety of oral methotrexate monotherapy for AA.
For the purpose, the researchers retrospectively reviewed the clinical course of AA patients including pediatric cases treated with methotrexate (MTX) monotherapy. Their detailed clinical data including final treatment outcomes, original severity of AA, side effects, and the duration until maximum response were assessed.
Statistical analysis was performed to evaluate if the clinical factors including the duration of current alopecia, age, the presence of body hair loss, and sex were associated with treatment response.
All included patients had severe AA and failed standard therapies.
Key findings of the study include:
Thirteen out of 15 cases demonstrated improvement during the monotherapy, and all responders demonstrated the maximum response within 1 year.
Female patients had significantly better outcomes than male patients.
Other factors did not significantly influence on the treatment outcome.
None of the patients experienced side effects that were severe enough to terminate the treatment.
"Our results support methotrexate (MTX) monotherapy as a feasible option for severe AA patients who fail other standard therapies or for whom systemic corticosteroids are contraindicated," concluded the authors.
Reference:
The study titled, "Oral Methotrexate Monotherapy for Severe Alopecia Areata: A Single Center Retrospective Case Series," is published in the Journal of Cutaneous Medicine and Surgery.
DOI: https://journals.sagepub.com/doi/10.1177/1203475421995712

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!